Literature DB >> 15947921

Transfer of rofecoxib into human milk.

Sharon J Gardiner1, Evan J Begg, Mei Zhang, Ruth C E Hughes.   

Abstract

OBJECTIVE: To determine the milk-to-plasma (M/P) concentration ratio of rofecoxib in lactating mothers and estimate likely infant exposure.
METHODS: Rofecoxib 25 mg was given to six lactating women at weaning. Blood and milk were sampled up to 72 h post-dose for determination of rofecoxib concentrations. M/P ratios were derived from the respective area under the concentration-time curves. The infant 'dose' in milk was estimated and expressed as a percentage of the maternal dose, corrected for weight.
RESULTS: The median (range) M/P ratio and infant 'dose' were 0.25 (0.16-0.32) and 2.1% (1.8-3.2%), respectively.
CONCLUSIONS: The use of rofecoxib during breastfeeding is unlikely to pose harm to the suckling infant on the basis of low transfer into human milk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947921     DOI: 10.1007/s00228-005-0937-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.

Authors:  Nikolaus A Haas; Robert Nossal; Christoph H Schneider; Martin A G Lewin; Volker Ocker; Martin Holder; Frank Uhlemann
Journal:  Pediatr Crit Care Med       Date:  2003-04       Impact factor: 3.624

2.  Determination of rofecoxib in human plasma and breast milk by high-performance liquid chromatographic assay.

Authors:  Mei Zhang; Grant A Moore; Sharon J Gardiner; Evan J Begg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-08-05       Impact factor: 3.205

3.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

4.  Studies in human lactation: milk volume and nutrient composition during weaning and lactogenesis.

Authors:  M C Neville; J C Allen; P C Archer; C E Casey; J Seacat; R P Keller; V Lutes; J Rasbach; M Neifert
Journal:  Am J Clin Nutr       Date:  1991-07       Impact factor: 7.045

5.  Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.

Authors:  Anirut Pattaragarn; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2003-07-18       Impact factor: 3.714

Review 6.  Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences.

Authors:  J T Wilson; R D Brown; D R Cherek; J W Dailey; B Hilman; P C Jobe; B R Manno; J E Manno; H M Redetzki; J J Stewart
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

7.  Bartter syndrome: benefits and side effects of long-term treatment.

Authors:  Maria Helena Vaisbich; Maria Danisi Fujimura; Vera H Koch
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

8.  Celecoxib in human milk: a case report.

Authors:  David C Knoppert; Diana Stempak; Sylvain Baruchel; Gideon Koren
Journal:  Pharmacotherapy       Date:  2003-01       Impact factor: 4.705

Review 9.  Use of antibiotic and analgesic drugs during lactation.

Authors:  Benjamin Bar-Oz; Mordechai Bulkowstein; Lilach Benyamini; Revital Greenberg; Ingrid Soriano; Deena Zimmerman; Oxana Bortnik; Matitiahu Berkovitch
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  9 in total
  2 in total

1.  Quantification of infant exposure to celecoxib through breast milk.

Authors:  Sharon J Gardiner; Matthew P Doogue; Mei Zhang; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

2.  Impact of transmammary-delivered meloxicam on biomarkers of pain and distress in piglets after castration and tail docking.

Authors:  Jessica L Bates; Locke A Karriker; Matthew L Stock; Kelly M Pertzborn; Luke G Baldwin; Larry W Wulf; C J Lee; Chong Wang; Johann F Coetzee
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.